Eli Lilly and Company announced that data from the Phase 3 LIBRETTO-432 study evaluating Retevmo (selpercatinib) as adjuvant therapy in patients with RET fusion-positive non-small cell lung cancer (NSCLC) will be featured in the Plenary Session and the ASCO press program at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 5-9, 2026, in Chicago.
The LIBRETTO-432 trial is a randomized, double-blind, placebo-controlled study assessing the efficacy and safety of Retevmo in patients with stage IB-IIIA RET fusion-positive NSCLC who have completed definitive therapy. The primary endpoint is event-free survival (EFS). This marks the first Phase 3 study of a RET inhibitor in the adjuvant setting for this patient population.
In addition, Lilly will present data from an investigator-initiated study of Verzenio (abemaciclib) in patients with advanced breast cancer, along with other oncology pipeline assets across multiple tumor types and treatment modalities. The full ASCO 2026 abstract titles will be released on May 13, 2026, at 5:00 PM ET.
Lilly's oncology portfolio includes approved medicines such as Verzenio (abemaciclib), Retevmo (selpercatinib), and Cyramza (ramucirumab), as well as investigational agents. The company continues to explore new indications and combinations to address unmet medical needs in cancer care.
